Stereotaxis Inc. (NYSEAMERICAN:STXS – Get Free Report)’s share price was down 2.5% during trading on Friday . The stock traded as low as $2.29 and last traded at $2.32. Approximately 399,166 shares changed hands during mid-day trading, an increase of 17% from the average daily volume of 340,709 shares. The stock had previously closed at $2.38.
Stereotaxis Trading Down 2.5%
The company has a 50-day simple moving average of $2.18 and a 200 day simple moving average of $2.12. The company has a market cap of $199.52 million, a P/E ratio of -7.48 and a beta of 1.44.
Institutional Investors Weigh In On Stereotaxis
A number of hedge funds have recently made changes to their positions in STXS. ProShare Advisors LLC lifted its stake in shares of Stereotaxis by 53.6% during the 4th quarter. ProShare Advisors LLC now owns 15,913 shares of the company’s stock worth $36,000 after purchasing an additional 5,556 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Stereotaxis during the 1st quarter worth $37,000. Two Sigma Securities LLC purchased a new stake in shares of Stereotaxis during the 4th quarter worth $54,000. Wells Fargo & Company MN lifted its stake in shares of Stereotaxis by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 26,915 shares of the company’s stock worth $61,000 after purchasing an additional 9,403 shares during the last quarter. Finally, Cherry Creek Investment Advisors Inc. raised its stake in Stereotaxis by 16.6% in the first quarter. Cherry Creek Investment Advisors Inc. now owns 40,866 shares of the company’s stock valued at $72,000 after buying an additional 5,825 shares during the last quarter. 45.35% of the stock is currently owned by hedge funds and other institutional investors.
Stereotaxis Company Profile
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Further Reading
- Five stocks we like better than Stereotaxis
- 3 Fintech Stocks With Good 2021 Prospects
- Why Pure Storage Is a Core Investment for the AI Era
- Basic Materials Stocks Investing
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.